| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 15 | 2017 | 184 | 2.730 |
Why?
|
| Neuropsychological Tests | 17 | 2019 | 243 | 2.590 |
Why?
|
| Veterans | 8 | 2015 | 69 | 2.230 |
Why?
|
| Alcoholism | 14 | 2024 | 119 | 2.130 |
Why?
|
| Military Personnel | 6 | 2015 | 47 | 2.030 |
Why?
|
| Stress, Psychological | 13 | 2019 | 221 | 2.030 |
Why?
|
| Brain Injuries | 6 | 2015 | 49 | 1.760 |
Why?
|
| Hydrocortisone | 11 | 2019 | 89 | 1.520 |
Why?
|
| Family Health | 11 | 2019 | 71 | 1.510 |
Why?
|
| Blood Platelets | 16 | 2020 | 206 | 1.310 |
Why?
|
| Male | 76 | 2025 | 13491 | 1.200 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2017 | 58 | 1.130 |
Why?
|
| Spinal Cord Injuries | 3 | 2013 | 56 | 1.110 |
Why?
|
| Female | 72 | 2025 | 15156 | 1.080 |
Why?
|
| Adult | 49 | 2024 | 7740 | 1.030 |
Why?
|
| Young Adult | 25 | 2024 | 2733 | 0.970 |
Why?
|
| Adolescent | 28 | 2025 | 3122 | 0.960 |
Why?
|
| Humans | 84 | 2025 | 28097 | 0.920 |
Why?
|
| Life Change Events | 3 | 2015 | 33 | 0.880 |
Why?
|
| Middle Aged | 36 | 2019 | 7138 | 0.820 |
Why?
|
| Substance-Related Disorders | 7 | 2024 | 185 | 0.790 |
Why?
|
| Multiple Sclerosis | 2 | 2013 | 87 | 0.770 |
Why?
|
| Cognition | 7 | 2017 | 324 | 0.750 |
Why?
|
| Aged | 30 | 2019 | 5400 | 0.680 |
Why?
|
| Risk Factors | 22 | 2020 | 2081 | 0.680 |
Why?
|
| Adult Survivors of Child Abuse | 4 | 2018 | 19 | 0.660 |
Why?
|
| Benchmarking | 1 | 2019 | 33 | 0.640 |
Why?
|
| Circadian Rhythm | 4 | 2019 | 76 | 0.630 |
Why?
|
| Arousal | 2 | 2018 | 38 | 0.630 |
Why?
|
| Brain Concussion | 2 | 2016 | 48 | 0.620 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 2021 | 0.610 |
Why?
|
| Child Abuse | 3 | 2019 | 92 | 0.600 |
Why?
|
| Ischemic Attack, Transient | 5 | 2020 | 25 | 0.590 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 122 | 0.580 |
Why?
|
| Naltrexone | 3 | 2018 | 19 | 0.570 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2025 | 7 | 0.560 |
Why?
|
| Independent Living | 1 | 2017 | 14 | 0.560 |
Why?
|
| Stroke | 5 | 2020 | 252 | 0.530 |
Why?
|
| Disability Evaluation | 2 | 2015 | 53 | 0.530 |
Why?
|
| Computers, Handheld | 1 | 2016 | 13 | 0.520 |
Why?
|
| Impulsive Behavior | 3 | 2015 | 14 | 0.510 |
Why?
|
| Mass Screening | 1 | 2017 | 152 | 0.510 |
Why?
|
| Outpatients | 2 | 2013 | 44 | 0.490 |
Why?
|
| Wheelchairs | 1 | 2015 | 5 | 0.480 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2546 | 0.480 |
Why?
|
| Disabled Persons | 1 | 2015 | 18 | 0.480 |
Why?
|
| Mobility Limitation | 1 | 2015 | 15 | 0.480 |
Why?
|
| Sex Characteristics | 6 | 2015 | 172 | 0.470 |
Why?
|
| Pressure Ulcer | 2 | 2013 | 11 | 0.460 |
Why?
|
| Caffeine | 7 | 2010 | 39 | 0.440 |
Why?
|
| 4-Aminopyridine | 1 | 2013 | 3 | 0.430 |
Why?
|
| Potassium Channel Blockers | 1 | 2013 | 10 | 0.430 |
Why?
|
| Gait | 1 | 2013 | 61 | 0.410 |
Why?
|
| Oklahoma | 10 | 2015 | 1007 | 0.410 |
Why?
|
| Dementia | 1 | 2014 | 94 | 0.400 |
Why?
|
| Motor Activity | 1 | 2013 | 148 | 0.400 |
Why?
|
| Age Factors | 6 | 2015 | 734 | 0.390 |
Why?
|
| Warfare | 1 | 2012 | 9 | 0.390 |
Why?
|
| Affect | 5 | 2015 | 85 | 0.390 |
Why?
|
| Health Status | 1 | 2013 | 148 | 0.390 |
Why?
|
| Individuality | 1 | 2011 | 19 | 0.380 |
Why?
|
| Walking | 1 | 2013 | 135 | 0.380 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 54 | 0.360 |
Why?
|
| Platelet Activation | 7 | 2011 | 54 | 0.360 |
Why?
|
| Stress, Physiological | 1 | 2011 | 96 | 0.360 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 521 | 0.320 |
Why?
|
| Rest | 1 | 2010 | 94 | 0.310 |
Why?
|
| Quality of Life | 1 | 2013 | 487 | 0.310 |
Why?
|
| Genetic Testing | 1 | 2009 | 68 | 0.310 |
Why?
|
| Retinal Diseases | 1 | 2009 | 47 | 0.310 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2019 | 10 | 0.300 |
Why?
|
| Child | 6 | 2025 | 2242 | 0.300 |
Why?
|
| Psychometrics | 2 | 2019 | 121 | 0.290 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2019 | 7 | 0.290 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 769 | 0.280 |
Why?
|
| Genotype | 7 | 2025 | 456 | 0.280 |
Why?
|
| Narcotic Antagonists | 3 | 2018 | 32 | 0.280 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 62 | 0.270 |
Why?
|
| Saliva | 6 | 2019 | 96 | 0.270 |
Why?
|
| Heart Rate | 5 | 2019 | 379 | 0.270 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 366 | 0.260 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 13 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2018 | 547 | 0.260 |
Why?
|
| Alzheimer Disease | 4 | 2011 | 220 | 0.260 |
Why?
|
| Case-Control Studies | 8 | 2024 | 722 | 0.260 |
Why?
|
| Reaction Time | 3 | 2019 | 94 | 0.250 |
Why?
|
| Time Factors | 7 | 2019 | 1592 | 0.250 |
Why?
|
| Nervous System Diseases | 3 | 2017 | 40 | 0.250 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 452 | 0.250 |
Why?
|
| Reference Values | 3 | 2016 | 199 | 0.250 |
Why?
|
| Night Blindness | 1 | 2025 | 2 | 0.240 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2025 | 9 | 0.240 |
Why?
|
| Double-Blind Method | 9 | 2018 | 417 | 0.240 |
Why?
|
| Myopia | 1 | 2025 | 19 | 0.230 |
Why?
|
| Refraction, Ocular | 1 | 2025 | 24 | 0.230 |
Why?
|
| Copper | 3 | 2011 | 49 | 0.230 |
Why?
|
| Leukocytes | 1 | 2024 | 71 | 0.220 |
Why?
|
| Carotid Stenosis | 2 | 2014 | 27 | 0.220 |
Why?
|
| Phenotype | 3 | 2018 | 681 | 0.220 |
Why?
|
| United States | 5 | 2017 | 2146 | 0.220 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 98 | 0.210 |
Why?
|
| Sex Factors | 3 | 2015 | 466 | 0.210 |
Why?
|
| Temperament | 4 | 2017 | 11 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2010 | 354 | 0.190 |
Why?
|
| Delay Discounting | 2 | 2018 | 6 | 0.190 |
Why?
|
| Tomography, Optical Coherence | 2 | 2021 | 91 | 0.190 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2011 | 31 | 0.190 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 6 | 0.190 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2021 | 5 | 0.190 |
Why?
|
| Gene Duplication | 1 | 2021 | 15 | 0.190 |
Why?
|
| Self Report | 2 | 2012 | 120 | 0.180 |
Why?
|
| Polymorphism, Genetic | 2 | 2019 | 165 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2021 | 520 | 0.170 |
Why?
|
| Parkinson Disease | 2 | 2012 | 46 | 0.170 |
Why?
|
| Ceruloplasmin | 3 | 2009 | 9 | 0.170 |
Why?
|
| Stroke, Lacunar | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 75 | 0.160 |
Why?
|
| Platelet Count | 4 | 2015 | 111 | 0.160 |
Why?
|
| Prevalence | 2 | 2012 | 497 | 0.160 |
Why?
|
| Hypertension | 3 | 2012 | 308 | 0.160 |
Why?
|
| Amnesia | 2 | 2011 | 9 | 0.160 |
Why?
|
| ROC Curve | 2 | 2017 | 144 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2012 | 19 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 2 | 2012 | 20 | 0.160 |
Why?
|
| Ranibizumab | 1 | 2019 | 2 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 250 | 0.160 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 8 | 0.160 |
Why?
|
| Choroidal Neovascularization | 1 | 2019 | 11 | 0.160 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2018 | 4 | 0.160 |
Why?
|
| Blindness | 1 | 2019 | 34 | 0.160 |
Why?
|
| Choroid | 1 | 2019 | 20 | 0.150 |
Why?
|
| Cerebral Hemorrhage | 2 | 2010 | 91 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2019 | 72 | 0.150 |
Why?
|
| Mental Disorders | 2 | 2017 | 110 | 0.150 |
Why?
|
| Visual Acuity | 1 | 2019 | 111 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2017 | 391 | 0.150 |
Why?
|
| Linear Models | 1 | 2018 | 202 | 0.150 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2018 | 23 | 0.140 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 8 | 0.140 |
Why?
|
| Cross-Over Studies | 7 | 2018 | 134 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 50 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 407 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 2 | 2006 | 32 | 0.120 |
Why?
|
| Age of Onset | 2 | 2013 | 70 | 0.120 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 7 | 0.120 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 22 | 0.120 |
Why?
|
| Disease Progression | 4 | 2025 | 473 | 0.120 |
Why?
|
| Receptors, Opioid, mu | 1 | 2015 | 22 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2013 | 271 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2014 | 191 | 0.120 |
Why?
|
| Personality | 1 | 2015 | 25 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 50 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 224 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2006 | 220 | 0.120 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 19 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 17 | 0.110 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 56 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 37 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2014 | 48 | 0.110 |
Why?
|
| Law Enforcement | 1 | 2013 | 6 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2019 | 408 | 0.110 |
Why?
|
| Antisocial Personality Disorder | 2 | 2011 | 12 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 107 | 0.110 |
Why?
|
| Thrombin | 5 | 2017 | 69 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 43 | 0.110 |
Why?
|
| Cause of Death | 1 | 2013 | 73 | 0.100 |
Why?
|
| Drug Tolerance | 4 | 2005 | 37 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 474 | 0.100 |
Why?
|
| Muscle Strength | 1 | 2015 | 230 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 93 | 0.100 |
Why?
|
| Stroop Test | 1 | 2012 | 8 | 0.100 |
Why?
|
| Employment | 1 | 2013 | 49 | 0.100 |
Why?
|
| Mars | 1 | 2012 | 5 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 59 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 248 | 0.100 |
Why?
|
| Fatigue | 1 | 2012 | 64 | 0.100 |
Why?
|
| Afghan Campaign 2001- | 1 | 2012 | 11 | 0.100 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Psychological Techniques | 1 | 2011 | 4 | 0.100 |
Why?
|
| Time | 1 | 2011 | 16 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2012 | 35 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2019 | 2379 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 59 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 81 | 0.090 |
Why?
|
| Biomarkers | 2 | 2012 | 765 | 0.090 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 183 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 45 | 0.090 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2009 | 9 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 961 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 37 | 0.090 |
Why?
|
| Memory | 2 | 2012 | 73 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2011 | 48 | 0.090 |
Why?
|
| Collagen | 4 | 2017 | 156 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 106 | 0.080 |
Why?
|
| Alcoholics | 1 | 2009 | 2 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 15 | 0.080 |
Why?
|
| Comprehension | 1 | 2009 | 19 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2025 | 1146 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2009 | 21 | 0.080 |
Why?
|
| Frontotemporal Dementia | 1 | 2009 | 4 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2009 | 64 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2015 | 433 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 971 | 0.080 |
Why?
|
| Gastrectomy | 1 | 2009 | 20 | 0.080 |
Why?
|
| Personality Inventory | 3 | 2015 | 26 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 169 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 8 | 0.080 |
Why?
|
| Potassium | 1 | 2008 | 42 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 22 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 32 | 0.080 |
Why?
|
| Brain | 1 | 2014 | 741 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 57 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2008 | 10 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 2008 | 31 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2007 | 22 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2008 | 85 | 0.070 |
Why?
|
| Kidney | 1 | 2008 | 286 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 968 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 1248 | 0.070 |
Why?
|
| Eating | 1 | 2006 | 70 | 0.060 |
Why?
|
| Wakefulness | 1 | 2005 | 24 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1013 | 0.060 |
Why?
|
| Patient Selection | 1 | 2006 | 148 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2005 | 34 | 0.060 |
Why?
|
| Speech | 2 | 2019 | 13 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2015 | 26 | 0.060 |
Why?
|
| TRPM Cation Channels | 1 | 2025 | 8 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 1 | 2025 | 8 | 0.060 |
Why?
|
| Proteoglycans | 1 | 2025 | 38 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2024 | 25 | 0.060 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2019 | 26 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 322 | 0.060 |
Why?
|
| Decision Making | 1 | 2006 | 175 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2009 | 611 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 208 | 0.050 |
Why?
|
| Monocytes | 1 | 2024 | 135 | 0.050 |
Why?
|
| Neutrophils | 1 | 2024 | 181 | 0.050 |
Why?
|
| Animals | 2 | 2014 | 10423 | 0.050 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 72 | 0.050 |
Why?
|
| Turkey | 1 | 2021 | 10 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 19 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 19 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 479 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2013 | 236 | 0.050 |
Why?
|
| Pedigree | 1 | 2021 | 155 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2021 | 95 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 803 | 0.050 |
Why?
|
| Random Allocation | 2 | 2015 | 151 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2021 | 269 | 0.040 |
Why?
|
| Risk-Taking | 2 | 2014 | 61 | 0.040 |
Why?
|
| Smoking | 2 | 2019 | 473 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 636 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 666 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 289 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 16 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 34 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 350 | 0.040 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2018 | 1 | 0.040 |
Why?
|
| gamma-Crystallins | 1 | 2018 | 1 | 0.040 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Endophenotypes | 1 | 2018 | 2 | 0.040 |
Why?
|
| LIM Domain Proteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Tonometry, Ocular | 1 | 2018 | 9 | 0.040 |
Why?
|
| Optic Disk | 1 | 2018 | 10 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 109 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 124 | 0.040 |
Why?
|
| Visual Fields | 1 | 2018 | 33 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 179 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 62 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2018 | 56 | 0.040 |
Why?
|
| Intraocular Pressure | 1 | 2018 | 62 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 51 | 0.040 |
Why?
|
| Glaucoma | 1 | 2018 | 53 | 0.040 |
Why?
|
| Surface Properties | 2 | 2008 | 134 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 234 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2015 | 11 | 0.030 |
Why?
|
| Social Perception | 1 | 2015 | 23 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 612 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2014 | 7 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 24 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 81 | 0.030 |
Why?
|
| Vascular Resistance | 2 | 2005 | 50 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 607 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2014 | 25 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2018 | 484 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 194 | 0.030 |
Why?
|
| Weapons | 1 | 2013 | 1 | 0.030 |
Why?
|
| Conducted Energy Weapon Injuries | 1 | 2013 | 1 | 0.030 |
Why?
|
| Escape Reaction | 1 | 2013 | 4 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 226 | 0.030 |
Why?
|
| Electroshock | 1 | 2013 | 6 | 0.030 |
Why?
|
| Bites and Stings | 1 | 2013 | 6 | 0.030 |
Why?
|
| Irritants | 1 | 2013 | 7 | 0.030 |
Why?
|
| Violence | 1 | 2013 | 31 | 0.030 |
Why?
|
| Running | 1 | 2013 | 39 | 0.030 |
Why?
|
| Aerosols | 1 | 2013 | 43 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 509 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 216 | 0.030 |
Why?
|
| Actigraphy | 1 | 2012 | 22 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2012 | 11 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 2012 | 28 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 16 | 0.020 |
Why?
|
| Phototherapy | 1 | 2012 | 28 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 38 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 887 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2012 | 37 | 0.020 |
Why?
|
| Sleep | 1 | 2012 | 108 | 0.020 |
Why?
|
| Temperance | 1 | 2011 | 5 | 0.020 |
Why?
|
| Breath Tests | 1 | 2011 | 14 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2011 | 25 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 2011 | 7 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 5 | 0.020 |
Why?
|
| Premenopause | 1 | 2010 | 20 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 253 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 83 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2011 | 118 | 0.020 |
Why?
|
| Hyperkalemia | 1 | 2008 | 8 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 20 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 3 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 48 | 0.020 |
Why?
|
| Signal Detection, Psychological | 1 | 2008 | 8 | 0.020 |
Why?
|
| Models, Structural | 1 | 2007 | 13 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2008 | 28 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 258 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 562 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 2006 | 7 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 254 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 24 | 0.020 |
Why?
|
| Gambling | 1 | 2006 | 9 | 0.020 |
Why?
|
| Behavior | 1 | 2006 | 14 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 21 | 0.020 |
Why?
|
| Telephone | 1 | 2006 | 26 | 0.020 |
Why?
|
| Crotalid Venoms | 1 | 2006 | 6 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 215 | 0.020 |
Why?
|
| Adrenal Cortex | 1 | 2005 | 13 | 0.020 |
Why?
|
| Education | 1 | 2006 | 33 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 58 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2006 | 119 | 0.020 |
Why?
|
| Secretory Rate | 1 | 2005 | 5 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2005 | 93 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 112 | 0.020 |
Why?
|
| Capsules | 1 | 2005 | 8 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 43 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 48 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2005 | 1 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 184 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 514 | 0.010 |
Why?
|